2012
DOI: 10.1083/jcb.201109105
|View full text |Cite
|
Sign up to set email alerts
|

Open chromatin structures regulate the efficiencies of pre-RC formation and replication initiation in Epstein-Barr virus

Abstract: Studies of EBV replication origins demonstrate an excess of pre-replication complexes that are formed at flexible MNase-sensitive sites in the genome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
26
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
6
1
1

Relationship

2
6

Authors

Journals

citations
Cited by 16 publications
(31 citation statements)
references
References 64 publications
5
26
0
Order By: Relevance
“…Lee et al, 2012;Papior, Arteaga-Salas, Gunther, Grundhoff, & Schepers, 2012). Mammalian replication is tightly regulated by a process called replication licensing that is modulated by the cell cycle and ensures that replication occurs once per cycle (Sclafani & Holzen, 2007;Truong & Wu, 2011).…”
Section: Papillomavirus Replicationmentioning
confidence: 99%
“…Lee et al, 2012;Papior, Arteaga-Salas, Gunther, Grundhoff, & Schepers, 2012). Mammalian replication is tightly regulated by a process called replication licensing that is modulated by the cell cycle and ensures that replication occurs once per cycle (Sclafani & Holzen, 2007;Truong & Wu, 2011).…”
Section: Papillomavirus Replicationmentioning
confidence: 99%
“…Interestingly, ORC binding sites are partially linked with patterns of gene expression [25,26]. One reason is that both transcriptional active promoters and DNA replication origins require a stretch of nucleosome-free DNA [27][28][29]. AT-or G-rich sequences promote nucleosome exclusion and are enriched at origins.…”
Section: Dna Replication Originsmentioning
confidence: 98%
“…With its defined origin sequence (oriP) and replication factors, it has become a powerful tool to study the initiation process of eukaryotic DNA replication [101105]. As the cellular mechanisms unfold, one can develop effective targeted therapy to eradicate the EBV latency.…”
Section: Epstein–barr Virus (Ebv): Taking Advantage Of Host Orcmentioning
confidence: 99%